Pfizer Common Stock Dividends Paid 2010-2024 | PFE
Pfizer annual/quarterly common stock dividends paid history and growth rate from 2010 to 2024. Common stock dividends paid can be defined as the cash outflow for dividends paid on a company's common stock
- Pfizer common stock dividends paid for the quarter ending September 30, 2024 were $-7.132B, a 2.89% increase year-over-year.
- Pfizer common stock dividends paid for the twelve months ending September 30, 2024 were $-23.503B, a 2.92% increase year-over-year.
- Pfizer annual common stock dividends paid for 2023 were $-9.247B, a 2.94% increase from 2022.
- Pfizer annual common stock dividends paid for 2022 were $-8.983B, a 2.91% increase from 2021.
- Pfizer annual common stock dividends paid for 2021 were $-8.729B, a 3.42% increase from 2020.
Pfizer Annual Common Stock Dividends Paid
(Millions of US $) |
| 2023 |
$-9,247 |
| 2022 |
$-8,983 |
| 2021 |
$-8,729 |
| 2020 |
$-8,440 |
| 2019 |
$-8,043 |
| 2018 |
$-7,978 |
| 2017 |
$-7,659 |
| 2016 |
$-7,317 |
| 2015 |
$-6,940 |
| 2014 |
$-6,609 |
| 2013 |
$-6,580 |
| 2012 |
$-6,534 |
| 2011 |
$-6,234 |
| 2010 |
$-6,088 |
| 2009 |
$-5,548 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$158.619B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
